
Social Worth Technologies Limited, the parent company of Fibe (formerly known as EarlySalary), filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) on June 29, 2026, for its proposed 100% book-built Initial Public Offering (IPO).
As per the DRHP, the IPO comprises a Fresh Issue of up to ₹750 crore and an Offer for Sale (OFS) of up to 4.007 crore equity shares, each with a face value of ₹5.
Specific details of the price band, lot size, Anchor Investor bidding date, and public subscription opening and closing dates are yet to be announced.
Explore other Upcoming IPOs on BSE and NSE.
The Company proposes to utilise the net proceeds from the Fresh Issue towards the following purposes:
Check out newly Listed IPOs on BSE and NSE.
Fibe is a digital consumer financing platform that provides affordable credit solutions across personal loans, education, healthcare, insurance, travel, and other consumption needs. The company leverages AI, machine learning, and data science to streamline customer onboarding, underwriting, risk management, and collections.
Driven by its technology-led model and expanding merchant network, Fibe has delivered strong growth. As of March 31, 2026, it managed assets under management (AUM) of ₹8,602.74 crore and operated a network of over 10,387 merchant touchpoints across India, enabling efficient customer acquisition and wider distribution of its financing products.
|
Particulars |
FY26 (in ₹ Cr.) |
FY25 (in ₹ Cr.) |
FY24 (in ₹ Cr.) |
|
Revenue from Operations |
1,584.54 |
1,208.94 |
771.86 |
|
Profit After Tax (PAT) |
257.46 |
113.73 |
101.24 |
|
EBITDA |
647.77 |
357.08 |
265.89 |
SEBI will now review the DRHP and may seek additional clarifications before issuing its observations. Upon receiving regulatory approval, Social Worth Technologies will file its Red Herring Prospectus (RHP), announce the price band, and open the IPO for public subscription.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory. To read the RA disclaimer, please click here.